Status
Conditions
Treatments
About
Restenosis due to myo-intimal hyperplasia remains a concern after carotid endarterectomy. It occurs in around 6% of cases. Several risk factors for restenosis have already been identified, such as smoking, hypertension, female gender, diabetes, dyslipidemia and small carotid diameter. The main objective of this prospective multicenter study was to determine whether the technical characteristics of the eversion technique have an influence on the rate of restenosis at 1 year.
Between September 2021 and November 2022, we followed all patients undergoing carotid endarterectomy by eversion in 8 French hospitals. Demographic data, operative indications and technical characteristics of the endarterectomies performed were collected. These were defined by the circumferential nature of the carotid bulb according to 3 types (TREC A, B or C), and the length and depth of the endarterectomy according to anatomopathological reports. Post-operative complications were collected as much as doppler ultrasonography at three months and 1 year to quantify restenosis.
Full description
Before the surgery, the following data is collected :
Data to be recovered post-operatively from carotid surgery :
The operative report specifying the circumferential nature of the carotid endarterectomy on the common carotid-external carotid axis.
3 possible categories: no endarterectomy, non-circumferential partial endarterectomy, circumferential endarterectomy.
Post-operative doppler (< 1 month) assessing the presence of residual stenosis.
The patient's operative consequences with the occurrence of intercurrent cardiological events (cardiological, biological or electrocardiographic), neurological (central or peripheral), post-operative complications such as cervical hematoma.
Visit between month 1 and month 3 :
Visit at one year :
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Any patient who is having carotid endarterectomy by eversion according to HAS + ESVS recommendations :
Exclusion criteria
Loading...
Central trial contact
Elise HOUSSIN; Gautier HAUPERT, Dr
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal